| ABT |
Report |
Adjusted EPS (Q2 2026) |
IN-LINE |
pred ~$1.29 vs. cons $1.28 |
MEDIUM |
| ABT |
Report |
Organic/comparable sales growth (Q2 2026) |
MISS |
pred ~8.0% vs. cons ~9.85% |
MEDIUM |
| ABT |
Report |
CGM / FreeStyle Libre sales (Q2 2026) |
MISS |
pred ~$2.10B (+11%) vs. cons ~$2.16B (+13%) |
MEDIUM |
| ABT |
Guide |
FY26 adj. EPS guide |
UNCHANGED |
guide reaffirmed ~$5.48 midpoint ($5.38–$5.58) vs. cons ~$5.48 (FY2026) |
MEDIUM |
| ABT |
Guide |
FY26 comparable sales growth guide |
UNCHANGED |
guide ~6.5–7.5% (mid ~7.0%) vs. cons ~7.0% (FY2026) |
MEDIUM |
| ABT |
Guide |
Q3 2026 adj. EPS guide |
LOWER |
guide ~$1.40 vs. cons ~$1.43 (Q3 2026) |
LOW |
| ABT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| ABT |
Return |
5-day cumulative residual |
-4.0% (FADE) |
The Street's ~9.85% Q2 comparable-growth bar is very aggressive versus Q1's +3.7%; even with an in-line/penny EPS beat, a shortfall on the 2H re-acceleration proof point (soft CGM and still-negative Nutrition) plus a reaffirmed-not-raised FY guide keeps the 'show-me' skepticism alive. This is the third potentially disappointing quality print of the year, and out-period math (Exact dilution, conservative respiratory/CGM assumptions, no CMS Type-2 upside baked in) means sell-side trims estimates modestly even on a headline hit — revisions drift lower after Day 1, extending the drawdown rather than a beaten-down-name bounce. |
LOW |